Vimarsana
Biggest News Aggregation in the World

Page 8 - Nasdaq Cdxc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Cdxc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cdxc Today - Breaking & Trending Today

ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to "Sell" - Vimarsana News

ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to "Sell"

Zacks Investment Research downgraded shares of ChromaDex (NASDAQ:CDXC – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]

ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to Sell - Vimarsana News

ChromaDex (NASDAQ:CDXC) Downgraded by Zacks Investment Research to Sell

ChromaDex (NASDAQ:CDXC – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and […]

$17.42 Million in Sales Expected for ChromaDex Co. (NASDAQ:CDXC) This Quarter - Vimarsana News

$17.42 Million in Sales Expected for ChromaDex Co. (NASDAQ:CDXC) This Quarter

Wall Street brokerages expect ChromaDex Co. (NASDAQ:CDXC – Get Rating) to report $17.42 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for ChromaDex’s earnings, with the lowest sales estimate coming in at $15.73 million and the highest estimate coming in at $19.00 million. ChromaDex posted sales of $14.68 […]

ChromaDex (NASDAQ:CDXC) Raised to Hold at Zacks Investment Research - Vimarsana News

ChromaDex (NASDAQ:CDXC) Raised to Hold at Zacks Investment Research

ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]

ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by Zacks Investment Research - Vimarsana News

ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by Zacks Investment Research

ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary […]